Vaxcyte, Inc. Stock

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:19:54 2024-05-30 pm EDT 5-day change 1st Jan Change
68.96 USD +1.53% Intraday chart for Vaxcyte, Inc. -0.52% +9.73%
Sales 2024 * - Sales 2025 * - Capitalization 7.39B
Net income 2024 * -452M Net income 2025 * -507M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-16.9 x
P/E ratio 2025 *
-15.6 x
Employees 254
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.53%
1 week-0.52%
Current month+13.81%
1 month+13.81%
3 months-3.90%
6 months+33.11%
Current year+9.73%
More quotes
1 week
67.21
Extreme 67.21
69.90
1 month
60.21
Extreme 60.21
76.00
Current year
53.83
Extreme 53.83
82.04
1 year
44.20
Extreme 44.2
82.04
3 years
16.78
Extreme 16.78
82.04
5 years
15.51
Extreme 15.51
82.04
10 years
15.51
Extreme 15.51
82.04
More quotes
Managers TitleAgeSince
Founder 60 13-05-26
Founder 56 13-05-26
Director of Finance/CFO 55 20-04-30
Members of the board TitleAgeSince
Founder 56 13-05-26
Director/Board Member 57 21-09-15
Director/Board Member 56 18-04-30
More insiders
Date Price Change Volume
24-05-30 69 +1.59% 69 234
24-05-29 67.92 -1.14% 362,562
24-05-28 68.7 -0.09% 439,691
24-05-24 68.76 -0.74% 480,352
24-05-23 69.27 -2.93% 577,112

Delayed Quote Nasdaq, May 30, 2024 at 12:05 pm EDT

More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
67.92 USD
Average target price
103.1 USD
Spread / Average Target
+51.86%
Consensus